|
Katholi [51]
|
sCr 1.4-2.0 mg/dl and rec contrast
|
Excluded
|
60 ± 4 (NMg), 61 ± 3 (LoMg)
|
59 ± 5 (NMg), 63 ± 4 (LoMg)
|
Not reported
|
Not reported
|
Not reported
|
Not reported
|
|
Perez-Ruiz [56]
|
Chronic Gout with CrCl 20-80
|
Not reported
|
60.9 ± 12.8
|
67.3 ± 9.59
|
Not reported
|
Not reported
|
9.35 ± 1.96
|
8.96 ± 1.84
|
|
Kamper [50]
|
HTN CsA Renal Tr
|
Minority
|
M median age 47, W median age 47
|
N/A
|
10:16
|
N/A
|
7.90 (median), 4.87-11.60 (range)
|
N/A
|
|
Schmidt [53]
|
HTN CsA Renal Tr
|
Not reported
|
58 ± 12
|
N/A
|
1:12
|
N/A
|
7.8 ± 2.2
|
7.8 ± 1.8
|
|
Doehner [35]
|
LV dysfxn (EF < 40%), hyperUA >400 umol/L
|
Not reported
|
68 ± 2
|
69 ± 3
|
100% male
|
100% male
|
8.99 ± 0.37
|
9.88 ± 0.62
|
|
Chanard [54]
|
HTN CsA Renal Tr
|
Not reported
|
45.2 ± 9.9
|
48.2 ± 11.5
|
7:17
|
8:16
|
8.11 ± 1.66
|
7.56 ± 1.65
|
|
Siu [48]
|
sCr 120-400 umol/L
|
Majority
|
47.7 ± 12.9
|
48.8 ± 16.8
|
9:4
|
13:15
|
9.75 ± 1.18
|
9.92 ± 1.68
|
|
Liu [36]
|
CKD (120-400 umol/L) and hyperUA
|
Not reported
|
45.6 ± 12.5
|
46.5 ± 13. 8
|
8:16
|
10:13
|
9.73 ± 0.20
|
9.92 ± 0.26
|
|
Sarris [34]
|
hyperUA > 7 mg/dL, mild-mod CKD, sCr >1.5, <3.0 mg/dL
|
Not reported
|
49.2 ± 17.3
|
50.4 ± 15.8
|
8:10
|
11:7
|
8.88 ± 1.26
|
9.16 ± 1.46
|
|
Lei [40]
|
CKD with hyperUA
|
Not reported
|
48.6 ± 10.2
|
49.5 ± 9.8
|
9:20
|
9:19
|
8.84 ± 1.45
|
8.70 ± 1.41
|
|
Malaguarnera [55]
|
hyperUA, 65-85 yrs, sCr 2.5 mg/dl
|
Approximately half
|
75.6 ± 8.4
|
76.4 ± 8.1
|
15:5
|
12:6
|
10.9 ± 2.9
|
10.3 ± 3.1
|
|
Nouri-Majalan [52]
|
Pts undergoing CABG and eGFR < 60
|
Not reported
|
65 ± 9.5
|
61 ± 7.90
|
13:17
|
16:14
|
Not reported
|
Not reported
|
|
Deng [37]
|
CKD
|
Not reported
|
60.0 ± 11.1
|
58.8 ± 9.4
|
15:14
|
14:18
|
8.59 ± 1.01
|
8.93 ± 0.96
|
|
Goicoechea [44]
|
CKD Stage 3-5
|
Majority
|
72.1 ± 7.9
|
71.4 ± 9.5
|
Not reported
|
Not reported
|
7.8 ± 2.1
|
7.3 ± 1.6
|
|
Momeni [46]
|
T2DM Nephropathy
|
Majority
|
56.3 ± 10.6
|
59.1 ± 10.6
|
11:9
|
11:9
|
5.96 ± 1.21
|
6.5 ± 2.2
|
|
Shen [38]
|
CKD with hyperUA
|
Not reported
|
47.1 ± 11.8
|
47.6 ± 12.4
|
8:18
|
9:17
|
9.01 ± 1.38
|
8.89 ± 1.50
|
|
Kao [45]
|
LVH and CKD Stage 3
|
Majority
|
70.6 ± 6.9
|
73.7 ± 5.3
|
59% male
|
46% male
|
7.39 ± 1.5
|
7.06 ± 1.3
|
|
Tan [39]
|
T2DM nephropathy eGFR, 30-60 ml/min/1.73 m2
|
Majority
|
59.3 ± 9.2
|
58.6 ± 8.3
|
35:37
|
33:35
|
8.93 ± 0.96
|
8.60 ± 1.01
|
|
Shi [47]
|
IgA nephropathy and hyperUA
|
Excluded
|
39.7 ± 10.0
|
40.1 ± 10.8
|
8:13
|
10:9
|
7.9 ± 1.1
|
7.8 ± 1.1
|
